Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Using smart* technology to predict where glucose levels are headed, Guardian™ Connect is the only smart continuous glucose monitor (CGM) that can predict high or low glucose excursions up to 60 minutes in advance.
Request a demoThe Guardian™ Connect CGM system can alert your patients 30 minutes sooner than other products, giving your patients more time to react and get ahead of high and low glucose levels.†
In a CareLink™ data analysis of real-world data,2 it was found that Guardian™ Connect system users avoided 65% of lows and 44% of high glucose episodes.‡
40%
of people with type 1 diabetes experience hypoglycemia unawareness3
49%
of people with type 2 diabetes experience one episode of hypoglycemia in 5 days4
98%
Low detection accuracy with predictive alerts turned on1
Anytime access to CGM data when patients link their CareLink™ account to your practice.
Remote access for virtual appointments in three easy steps:
A representative can keep you informed about new and existing Medtronic products. For more information, please fill out the form.
Participate in one of our free interactive webinars or view videos of our previously recorded webinars at your convenience.
View webinarsBrowse our library to find reference materials for our Medtronic Diabetes products.
Visit librarySmart CGM predicts future high and low sensor glucose events up to 60 minutes in advance.
Other CGM's provide predictive alerts up to 30-minutes per respective user guides.
Low episodes defined as ≤ 70 mg/dL in sensor glucose level; high episode as ≥ 180 mg/dL in sensor glucose level.
Guardian™ Connect SSED, page 19, Table 5. 98.5% Glucose Correct Detection Rate based on Predictive Alerts at 30 minutes when worn on the abdomen; Data includes all US patients uploading voluntarily to CareLink™ Personal software from June 2018 to Feb 2019 N=802. Patients included might be on other diabetes therapy, including insulin pumps, multiple daily injections or oral medications.
Arunachalam S, et al. Poster presented at ADA 2019. 79th Scientific Sessions. June 7th-11th. San Francisco, California. #939-P; Data includes all US patients uploading voluntarily to CareLink™ Personal Software from June 2018 to Feb 2019 N=802. Patients included might be on other diabetes therapy, including insulin pumps, multiple daily injections or oral medications
Martín-Timón, Cañizo-Gómez. Diabetes. 2015;6(7):912.
Gehlaut, Richa R., et al. J Diab Science Tech. 2015;9(5):999-1005.
Important Safety Information: Guardian™ Connect CGM System
The Guardian™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides and important safety information.
Important Safety Information: CareLink™ Software
The CareLink™ software is intended for use as a tool to help manage diabetes. The purpose of the software is to take information transmitted from insulin pumps, glucose meters and continuous glucose monitoring systems, and turn it into CareLink™ reports. The reports provide information that can be used to identify trends and track daily activities—such as carbohydrates consumed, meal times, insulin delivery, and glucose readings. NOTE: CareLink™ report data is intended for use as an adjunct in the management of diabetes only and NOT intended to be relied upon by itself. Patients should consult their healthcare providers familiar with the management of diabetes prior to making changes in treatment. For more details, please consult important safety information. and the appropriate CareLink™ User Guide at http://www.medtronicdiabetes.com/support/download-library/user-guides.